Cannabinoid Testing

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

HEADQUATERS

Contract Value

Not provided

Codes & Classification
Solicitation Number

15DDHQ25Q00000121

NAICS

541380 - Testing Laboratories and Services

Classification Code

H966

Additional Details
Set Aside

NONE

Place of Performance

Springfield, Virginia, UNITED STATES

SourceSAM
Documents3
The Drug Enforcement Administration (DEA), under the Department of Justice, has issued a solicitation for "Cannabinoid Testing" with the procurement identifier 15DDHQ25Q00000121. This procurement seeks to engage qualified contractors to conduct comprehensive evaluations of the abuse potential of both synthetic cannabinoids and phytocannabinoids through in vivo pharmacological studies. The primary objective is to generate scientifically robust data that will inform regulatory and enforcement decisions regarding these substances. The scope of work encompasses the design and execution of in vivo studies to assess the pharmacological effects and abuse liability of various cannabinoid compounds. Contractors are expected to utilize established laboratory methodologies and adhere to rigorous scientific standards to ensure the validity and reliability of results. The anticipated deliverables include detailed study protocols, data sets, analytical reports, and comprehensive final reports summarizing findings and their implications for public health and regulatory policy. This opportunity is classified under NAICS code 541380, which pertains to Testing Laboratories and Services, and is further identified by the Product Service Code H966. The place of performance is specified as Springfield, Virginia, United States. There are no set-aside restrictions associated with this solicitation, making it open to all qualified entities regardless of size or socioeconomic status. The contracting activity is managed by the DEA Headquarters Office, with Ms. Angel Barkley serving as the primary point of contact for all inquiries related to this notice. Interested parties may reach her via email at [email protected]. The solicitation was posted on January 29, 2026, and responses are due by February 9, 2026. Contractors considering this opportunity should possess demonstrated expertise in pharmacological testing, particularly in the context of controlled substances, and have the capacity to conduct complex in vivo studies in compliance with federal standards. The engagement will require strict adherence to scientific protocols, data integrity, and timely delivery of all required documentation. Further details, including solicitation attachments, can be accessed through the official SAM.gov opportunity page at https://sam.gov/opp/6f807a9627f84ebb873ae1640ad56b7e/view.